COMPASS PATHWAYS PLC
CMPSNASDAQTrading Snapshot
- Day Range
- $11.97 – $12.50
- 52-Week Range
- $4.88 – $15.87
- Volume (shares)
- 1,379,844
- Avg Volume (shares)
- —
- Shares Outstanding
- 138.5M
- Next Earnings
- 2026-11-02
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -2.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-4.21
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +36.8%
COMPASS PATHWAYS PLC
CMPS
StockOtter · stockotter.spaceAbout COMPASS PATHWAYS PLC
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today annou
Compass Pathways: A Compelling Opportunity In A Large And Underserved Market
COMPASS Pathways is currently engaged in a rolling submission and review with the FDA for COMP360 and expects a commercial launch in the first half of 2027. COMPASS is initially targeting the TRD market, which is large a
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced t
Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Sales
COMPASS Pathways is rated Buy, with high risk, based on strong trial design and imminent FDA review for COMP360 in treatment-resistant depression. COMP360's Phase 3 trials matched FDA guidance, achieved statistically sig
Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today annou
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that